PCSK9 Forum  
Click here to forward this email to a colleague
Facebook Twitter RSS YouTube linkedin
Home  |  About  |  PCSK9  |  News  |  Commentary  |  Trials  |  Videos  |  Resources  |  Contact
AHA 18

The Word from the 2018 American Heart Association Scientific Sessions
What made the news at this year’s meeting?

Lipoprotein(a)

Lipoprotein(a) was a key focus. First, the 2018 US Cholesterol Guidelines incorporated elevated lipoprotein(a) as a marker of cardiovascular risk. Second, a Latebreaker session showed a favourable benefit versus risk profile for a novel antisense oligonucleotide specific to the apolipoprotein(a) component of lipoprotein(a).

Now the stage is truly set to test the ‘lipoprotein(a) hypothesis’ with a phase III trial to evaluate whether lowering elevated lipoprotein(a) levels reduces cardiovascular events.

PCSK9 Forum Editor Professor John Chapman gives his take home messages about lipoprotein(a)

VIDEO

PCSK9 Forum Editor Professor John Chapman gives his take home messages about lipoprotein(a)

Watch the video »


ODYSSEY OUTCOMES

There were important new insights from the ODYSSEY OUTCOMES Trial with the PCSK9 monoclonal antibody alirocumab in acute coronary syndrome patients. Specifically, these new findings related to the impact of longer exposure to alirocumab on mortality, the relevance of baseline LDL cholesterol level to treatment benefit, and the impact of alirocumab on the total cardiovascular disease burden in these very high-risk patients. Additionally, a cost-effectiveness analysis showed the health value associated with alirocumab in preventing cardiovascular events and death in the post-acute coronary syndrome setting from a USA payer perspective.

Lead Investigator of the ODYSSEY OUTCOMES Trial, Professor Gregory G. Schwartz (University of Colorado, Denver, USA) comments on these new findings.

PCSK9 Forum Editor Professor John Chapman gives his take home messages about lipoprotein(a) PCSK9 Forum Editor Professor John Chapman gives his take home messages about lipoprotein(a)
VIDEO: New insights from ODYSSEY OUTCOMES

Watch the video »

 

VIDEO: Perspective on the ODYSSEY OUTCOMES Economic Study

Watch the video »

Clinicians and researchers can look forward to exciting new developments in the lipid field in 2019.

Like us on Facebook
For the latest updates, PCSK9 news and analysis
.
Follow us on Twitter
Hot topics, news and conference reports.
YouTube Channel
For videos, interviews and webcasts from leading experts.
Our popular therapeutic guide

Read online & download second edition now »

Register now at www.pcsk9forum.org to receive the updated third edition coming soon.
New eBook
Questions & Answers

Why are new treatments needed?


Read the full answer and other questions on the PCSK9 Forum »
Educational Partners
and Supporters
Amgen The Medicines Company Sanofi
Copyright PCSK9 Forum 2018. Please click here to unsubscribe from future mailings.